Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Harvard Business School
Citi
Healthtrust
Johnson and Johnson

Generated: September 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,372,872

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,372,872 protect, and when does it expire?

Patent 8,372,872 protects ULORIC and is included in one NDA.

This patent has thirteen patent family members in eleven countries.

Summary for Patent: 8,372,872
Title:Methods for concomitant treatment of theophylline and febuxostat
Abstract: Co-administration of febuxostat and theophylline to a hyperuricemic patient suffering from gout is disclosed.
Inventor(s): Gunawardhana; Lhanoo (Pleasant Prairie, WI), Naik; Himanshu (Evanston, IL), Tsai; Max (Highland Park, IL)
Assignee: Takeda Pharmaceuticals U.S.A., Inc. (Deerfield, IL)
Application Number:13/295,696
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,372,872
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,372,872

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-001 Feb 13, 2009 AB RX Yes No   Try a Free Trial   Try a Free Trial USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE   Try a Free Trial
Takeda Pharms Usa ULORIC febuxostat TABLET;ORAL 021856-002 Feb 13, 2009 AB RX Yes Yes   Try a Free Trial   Try a Free Trial USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,372,872

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011299153   Try a Free Trial
Brazil 112013005792   Try a Free Trial
Canada 2812034   Try a Free Trial
China 103298466   Try a Free Trial
European Patent Office 2613780   Try a Free Trial
Spain 2532210   Try a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Fuji
Merck
Cantor Fitzgerald
Johnson and Johnson
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.